To summarise, the data presented here support the hypothesis that at least some breast cancer patients, who develop severe reactions to radiotherapy, have an intrinsic radiosensitivity that can be identified in peripheral blood lymphocytes by quantifying gene expression response to IR and that CDKN1A is a surrogate marker for early effects of radiation therapy. Here, CDKN1A is linked to breast cancer.